logo-loader

Athersys, Inc surprises with move into the black

Last updated: 17:25 11 Mar 2016 GMT, First published: 12:25 11 Mar 2016 GMT

AZN6_56e3009c6ab32
The company is developing MultiStem therapy, a proprietary non-embryonic, allogeneic stem cell product candidate,

Regenerative medicine-focused biotech Athersys, Inc (NASDAQ:ATHX) put some vim into its share price with well-received fourth quarter results.

The company moved into profit, with net income of $3.59mln, equivalent to four cents a a share, versus market expectations of a loss per share of nine cents.

The fourth quarter profit reduced the loss for the year to $16.4mln, or a loss per share of 20 cents.

Nevertheless, the full-year loss was an improvement on 2014's loss of $22.1mln.

Revenues to $11.95mln in 2015 from $1.62mln the year before. Of the $11.95mln raked in, $10.61mln came in the fourth quarter, which was way ahead of the $3.72mln tipped by analysts that follow the stock.

Shares rose 17% to $2.14 on the results.  

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 39 minutes ago